Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01033500 |
Recruitment Status
:
Withdrawn
(Insufficient funding)
First Posted
: December 16, 2009
Last Update Posted
: May 8, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Islets of Langerhans Transplantation Diabetes Mellitus, Type 1 Kidney Transplantation | Drug: Belatacept | Not Applicable |
This is a single center, open-label, non-randomized, prospective, pilot study of 8 Type 1 diabetic/uremic patients, ages 18-60 undergoing simultaneous islet-kidney transplantation. Study to include both male and/or female subjects.
We hypothesize that a calcineurin inhibitor-free, steroid-free, co-stimulatory blockade-based immunosuppressive regimen, in combination with a GLP-1 agonist, will reduce the islet mass required to achieve and sustain insulin independence following simultaneous islet-kidney transplantation.
Furthermore, we anticipate an improvement in creatinine clearance and a reduction in Interstitial Fibrosis/Tubular Atrophy in the transplanted renal allograft, and a reduction of "de novo" human anti-HLA antibody and auto-antibody formation against the respective donors.
Without calcineurin inhibitors or steroids, we hypothesize that belatacept, in conjunction with sirolimus and mycophenolic acid will provide balanced immunosuppression for combined islet-kidney transplantation.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients |
Study Start Date : | July 2010 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | December 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: SIK
Basiliximab induction with maintenance immunosuppression consisting of belatacept, sirolimus or everolimus, and mycophenolate after simultaneous islet kidney transplantation.
|
Drug: Belatacept
Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.
|
- Achieve and consistently maintain insulin independence in simultaneous islet-kidney transplant recipients for one year. [ Time Frame: 1 year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Subjects will include those with Type 1 Diabetes Mellitus, undergoing kidney transplantation, and:
- are closely followed by a primary care provider and/or endocrinologist for >6 months prior to enrollment in the trial
- do not have psychogenic factors which preclude therapeutic compliance
- have a fasting C-peptide of <0.2 ng/mL• have diabetes for >5 years • are between 18 and 65 years of age
- have a creatinine clearance of less than 20 mL/min
- have a body mass index of less than or equal to 28
- In the case of women of childbearing potential (WOCBP), must have a negative pregnancy test and avoid pregnancy throughout the study and 8 weeks after final dose of study drug.
- WOCBP must use two adequate methods of contraception.
- A male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study and for up to 8 weeks after the last dose of study drug to minimize the risk of pregnancy.
Exclusion Criteria:
-
Untreated proliferative diabetic retinopathy
- HgbA1C >12
- creatinine clearance > 20 ml/minute
- presence of panel reactive antibodies (PRA) >20% (per CDC-based assay)
- malignancy or previous malignancy, except for adequately treated skin cancers (basal cell or squamous cell carcinoma) within the past 5 years
- sensitivity to iodine and/or shellfish (re: Iothalamate-based GFR testing)
- x-ray evidence of pulmonary infection
- active infections
- active peptic ulcer disease, gall stones, hemangioma, cirrhosis or portal hypertension
- serological evidence of HIV, HBSAg or HCV
- abnormal liver function tests (elevated AST and ALT > 2x upper limit of normal)
- anemia (hemoglobin) <9 gm/dl
- serum triglycerides >200 mg/dl
- serum cholesterol >240 mg/dl
- body mass index above 28
- unstable cardiovascular status (including positive stress echocardiography if >age 35); severe coexisting cardiac disease, myocardial infarction within the 6 months prior to enrollment in the study, left ventricular ejection fraction of <30%, or evidence of ongoing ischemia
- prostate specific antigen (PSA) >4 in males >40 years old or with family history of prostate cancer
- pregnancy or breastfeeding
- sexually-active females who are not: a) post-menopausal, b) surgically sterile, or c) not using an acceptable method of contraception (oral contraceptives, Norplant, Depo-Provera, and barrier devices are acceptable; condoms used alone are not acceptable)
- alcohol abuse, substance abuse or smoking within the previous 6 months
- insulin requirement >1.5 u/kg/day
- negative for Epstein-Barr virus by IgG determination
- history of factor V deficiency
- acute or chronic pancreatitis
- recurrent attenuated vaccine(s) within the previous 2 months
- use of an investigational agent within the past 4 weeks
- sexually active, fertile men not using effective birth control, if their partners are WOCBP
- prisoners, or subjects who are involuntarily incarcerated
- subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
- Previous kidney transplant or previous non-renal transplant
- kidney transplant from expanded criteria donor (ECD)
- kidney cold ischemic time projected to be > 20 hours
- currently receiving immunosuppressive agents for autoimmune disease or other conditions or have comorbidities that treatment with such agents are likely during the trial
- any condition or circumstance that makes it unsafe to undergo an islet cell or kidney transplant

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01033500
United States, Wisconsin | |
University of Wisconsin | |
Madison, Wisconsin, United States, 53792 |
Principal Investigator: | Luis Fernandez, MD | University of Wisconsin, Madison |
Responsible Party: | University of Wisconsin, Madison |
ClinicalTrials.gov Identifier: | NCT01033500 History of Changes |
Other Study ID Numbers: |
H-2010-0042 |
First Posted: | December 16, 2009 Key Record Dates |
Last Update Posted: | May 8, 2013 |
Last Verified: | May 2013 |
Additional relevant MeSH terms:
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases Immunosuppressive Agents |
Abatacept Calcineurin Inhibitors Immunologic Factors Physiological Effects of Drugs Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antirheumatic Agents |